-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $18

Benzinga·02/25/2026 13:16:39
Listen to the news
Wedbush analyst Laura Chico maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and lowers the price target from $20 to $18.